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Most pediatric tumors have only very few somatic
mutations. However, a recent study revealed that a
subset of tumors from children with congenital
biallelic deficiency of DNA mismatch repair exhibits a
mutational load surpassing almost all other cancers. In
these ultra-hypermutated tumors, somatic mutations in
the proofreading DNA polymerases complement the
congenital mismatch repair deficiency to completely
abolish replication repair, thereby driving tumor
development. These findings open several possibilities
for exploiting ultra-hypermutation for cancer therapy.match repair deficiency (bMMRD) by whole genomeCancer mutational load varies over several orders
of magnitude
Whole genome sequencing of hundreds to thousands of tu-
mors from several cancer types has drastically increased
our understanding of mutated cancer genomes. The muta-
tional load of tumors from different cancer types varies over
several orders of magnitude. At one extreme are most
childhood cancers, with pediatric mixed-lineage leukemia-
rearranged acute lymphoblastic leukemia having the lowest
numbers observed yet in any cancer, with a median of only
111 somatic single-base mutations (SSMs) genome-wide
[1]. At the other extreme are many hypermutated cancers,
such as lung cancers or cutaneous melanoma, with hun-
dreds of thousands of SSMs [2].
Hypermutation in cancer can be caused by exposure to
exogenous mutagens (for example, UV light in melanoma
or tobacco smoke in lung cancer) or endogenous muta-
genic processes (for example, activation-induced deaminase
in chronic lymphocytic leukemia and B-cell lymphomas
and excessive APOBEC activity in multiple cancers) [3]. Al-
ternatively, hypermutation can also be a consequence of de-
fects in DNA repair mechanisms that normally ensure
replication fidelity. In particular, two mechanisms limit the
error rate during DNA replication to roughly one to five* Correspondence: m.schlesner@dkfz-heidelberg.de
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unless otherwise stated.errors per cell division. Firstly, the proofreading ability of
DNA polymerase δ and ε efficiently corrects most misincor-
poration events directly during DNA synthesis. Secondly,
the DNA mismatch repair (MMR) system recognizes and
corrects the remaining errors that arise during replication
and also repairs several forms of DNA damage, thereby pre-
venting the manifestation of mutations in the next round of
replication. A third form of hypermutation affecting the in-
active X chromosome seems to be present in virtually all
cancers from female patients and shows no correlation to
specific mutational signatures or DNA repair defects [4].
In a recent study, Adam Shlien and colleagues investi-
gated tumors from children with congenital biallelic mis-
and exome sequencing [5]. Strikingly, all malignant brain
tumors from bMMRD patients showed extremely large
numbers of SSMs with an average of 249 SSMs per
megabase. This mutation rate exceeds the average
mutation rate even of highly mutated adult cancers by
one order of magnitude; thus, they are called ‘ultra-
hypermutated’.Ultra-hypermutation requires a second hit on the
DNA safeguards
A secondary mutation in one of the proofreading polymer-
ases δ and ε has been observed in all ultra-hypermutated
cancers. The combination of congenital bMMRD and som-
atic PolD1/PolE mutations abolishes both key mechanisms
to guarantee replication fidelity. Non-neoplastic tissue from
bMMRD patients (which lacks PolD1/E mutations) did not
show increased mutation numbers, indicating that the sec-
ond hit is a prerequisite for ultra-hypermutation. bMMRD
alone seems to lead to slow accumulation of mutations over
time, resulting in moderately increased mutational load in
bMMRD tumors lacking polymerase mutations, compared
with MMR-intact tumors of the same tissue. Unless a sec-
ond mutation in PolD1/PolE opens the door for ultra-
hypermutation, it can take years until a sufficient number
of drivers is acquired. Interestingly, mutations in either
PolD1 or PolE give rise to ultra-hypermutation in bMMRD
cells. However, while both bMMRD/PolD1 and bMMRD/
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PolE-mutated tumors are dominated by C >A and T >G
transversions in a TCT or TTT context, respectively, while
PolD1-mutated tumors bear predominantly C >A transver-
sions in a CCN context. Since the PolD1 and PolE muta-
tions affect the intrinsic proofreading activity, the observed
mutational patterns could reflect the initial error signatures
of the polymerases.
Ultra-hypermutation as a driver of cancer
progression
The impact of hypermutation on cancer initiation and pro-
gression is not always clear. Generally, a higher mutational
load increases the probability that a cell acquires sufficient
driver mutations to undergo malignant transformation.
However, hypermutation in a fully developed tumor might
also be a passenger effect resulting from DNA repair
deficiency acquired during tumor evolution. The PolD1 and
PolE mutations in the bMMRD/polymerase tumors oc-
curred early in the development of the tumors and affected
highly conserved residues. Additionally, these tumors almost
completely lacked DNA copy number variants, suggesting
that bMMRD/polymerase tumors are virtually exclusively
SSM-driven. This suggests that the complete breakdown of
replication repair, resulting in an explosion of SSMs, is an
early mechanism associated with tumor initiation and drives
tumor progression.
In another recent study, Supek and Lehner have shown
that the lower mutation rates observed in early replicating
regions of cancer genomes are due to more effective
MMR and not due to different initial mutation rates [6].
Virtually all genes fulfilling essential cellular functions are
early replicating. Hence, enhanced MMR in early replicat-
ing regions might be a protective mechanism to prevent
damage of essential cellular mechanisms. Hypermutation
caused by deficient DNA repair is not suppressed in early
replicating regions, thereby undermining this protection.
Therefore, with a similar number of genome-wide muta-
tions spread evenly across the genome, hypermutation
caused by defective DNA repair could have a higher prob-
ability than hypermutation caused by mutagens to affect
early replicating genes and thus result in a fatal combin-
ation of mutations leading to malignant transformation.
This might explain why DNA repair deficiencies such as
bMMRD lead to tumor development during childhood in
virtually all patients, while cancers associated with muta-
gen exposure often arise only after decades.
What are the implications for treatment?
It can be expected that ultra-hypermutated cancers, due to
their enormous mutation rate, exhibit sufficient genomic
flexibility to rapidly acquire resistance against most therapies
and, in particular, targeted therapies. Indeed, since the high
mutation rate results in enormous tumor heterogeneity,most likely already at the beginning of a therapy, the mu-
tations conferring resistance to the chosen drug will be
present in a subset of tumor cells. On the other hand, as
suggested by Shlien and colleagues, repair deficiency and
the high mutational load might be the Achilles’ heel of
ultra-hypermutated tumors. There seems to be an upper
boundary for the mutational load in cancer. The cells
from bMMRD/polymerase cancers acquire up to 600 new
mutations with each cell division. However, when 10,000
to 20,000 exonic mutations are reached, the tumors seem
to hit an upper limit of the tolerable mutational load. Nei-
ther pediatric nor adult cancers with constitutional and
somatic MMR/polymerase defects exceeded this mutation
level [2,3,5]. Considering this upper boundary for the mu-
tational load, the already huge number of mutations and
the complete lack of replication repair should make ultra-
hypermutated cancer cells highly sensitive to DNA-
damaging agents. However, in pediatric patients in general,
and in children with congenital MMR-deficiency in particu-
lar, these drugs have a very high risk of severe side effects,
including an increased risk for secondary tumors.
Other strategies to exploit ultra-hypermutation for cancer
therapy might be safer options. The upper boundary for the
mutational load indicates that ultra-hypermutated tumor
genomes are at a point where damage of additional genes
confers a likely selective disadvantage because essential cel-
lular functions are impaired. Therefore, ultra-hypermutated
cancers might be good candidates for exploitation of pas-
senger vulnerabilities as proposed by Aksoy, Sander and
others [7]. This approach focuses on essential cellular func-
tionalities, which can be carried out by multiple partner
proteins - for example, isoenzymes. If the tumor cells lose
all but one partner protein due to mutational inactivation,
the remaining partner will be essential for tumor cells, but
not for normal cells. Inhibition of the remaining partner
will thus specifically hit tumor cells. Since this therapeutic
strategy is based on functionalities that the tumor has lost
(and which usually cannot be gained again through add-
itional mutations), it can be expected to be more robust
against the development of resistance mechanisms than
other targeted therapies. However, the challenge in this
strategy is to identify defects that occurred very early on in
the tumor development, and is further complicated by the
requirement for biallelic defects. Otherwise, the presence of
tumor cells without the targeted defect will guarantee
tumor growth and impede sustained response to therapy.
Other possible strategies to exploit are immunotherapies
[8], given the high number of mutations that might render
ultra-hypermutated cancers more easily targetable than
other tumor types. Immunotherapies exploit the fact that
cancer cells expose antigens not found on normal cells.
Such tumor-specific antigens arise when mutations gener-
ate protein sequences normally not present in the human
body. With several thousands of exonic mutations, ultra-
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tumor-specific antigens and should thus be promising tar-
gets for a tumor-specific immune response.
Genome analysis of bMMRD tumors has inspired several
new therapeutic options for children with bMMRD-associ-
ated cancer. Since mismatch repair deficiency (MMRD) is
common in many cancers, studying bMMRD tumors might
aid the understanding of how and when MMRD contributes
to tumor progression. Finally, investigation of bMMRD tu-
mors may provide general insights into cancer biology: with
10,000 to 20,000 exonic mutations per tumor, in a cohort of
moderate size every gene will be affected by random muta-
tions. Potentially deleterious mutations will not be observed
only in those genes, where impaired function is a selective
disadvantage for the cancer cells. Analysis of the significantly
unmutated genes in a cohort of ultra-hypermutated tumors
can thus reveal cellular functions that are essential for can-
cer cells.
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